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We investigated the impact of parenteral antibiotic treatment in the early neonatal period on the evolution of biﬁdobacteria in
the newborn. Nine babies treated with intravenous ampicillin/gentamicin in the ﬁrst week of life and nine controls (no antibiotic
treatment) were studied. Denaturing gradient gel electrophoresis was used to investigate the composition of Biﬁdobacterium in
stool samples taken at four and eight weeks. Biﬁdobacteria were detected in all control infants at both four and eight weeks, while
only six of nine antibiotic-treated infants had detectable biﬁdobacteria at four weeks and eight of nine at eight weeks. Moreover,
stool samples of controls showed greater diversity of Biﬁdobacterium spp. compared with antibiotic-treated infants. In conclusion,
short-term parenteral antibiotic treatment of neonates causes a disturbance in the expected colonization pattern of biﬁdobacteria
in the ﬁrst months of life. Further studies are required to probiotic determine if supplementation is necessary in this patient
group.
1.Introduction
Up to 10% of newborn infants require admission to the
neonatal intensive care unit (NICU) for ongoing medical
care [1–3]. Many of these infants require treatment with
parenteral antibiotics for variable periods of time. Antibiotic
administration is known to perturb the composition of the
intestinal microbiota, resulting in suppression of anaerobic
bacteria (with the exception of clostridia, which remain
at detectable levels) and increased numbers of potentially
pathogenicbacteriasuchasKlebsiella,Enterobacter,Citrobac-
ter, and Pseudomonas [4, 5]. Since the pioneering microbiota
of infancy probably create perpetual habitats for themselves,
deﬁning the life-long composition of the gut microbiota
and consequently contributing to host health and well-being
[6, 7], the initial colonization of the infant gastrointestinal
tract is of signiﬁcant importance.
Biﬁdobacterium spp. have several reported health-
promoting eﬀects, including inhibition of growth of harmful
bacteria, stimulation of the immune system, alleviation of
constipation, and prevention of intestinal infections [8–
13]. Species commonly associated with humans include
Biﬁdobacterium infantis, B. longum, B. biﬁdum, B. breve,
B. catenulatum, B. pseudocatenulatum, B. angulatum, B.
gallicum, and B. adolescensis [8], of which the ﬁrst four are
prevalent in infants [14].
Suppression of the biﬁdobacteria population as occurred
followingantibioticexposureinchildren[5,15,16]mayhave
negativeeﬀectsonhostwell-beingandcanbeassociatedwith
higher susceptibility to enteropathogenic bacterial infection
[17]. However, the impact, if any, of parenteral antibiotics
prescribed shortly following birth on the developing biﬁ-
dobacterial population has not been addressed. The aim
of this study was therefore to determine the impact of2 International Journal of Microbiology
Table 1: Description of infant samples.
Sample Sex∗ Feeding∗∗ Antibiotic treatment (days) Type of Antibiotics† Mode of delivery
A M B + (9) Amp. + Gent. Caesarean section
B‡ M F + B + (5) Amp. + Gent. Caesarean section
C‡ M B + (2) Amp. + Gent. Caesarean section
D M F + (2) Amp. + Gent. Vaginal delivery
E F F + (5) Amp. + Gent. Caesarean section
F F B + (2) Amp. + Gent. Vaginal delivery
G F B + (2) Amp. + Gent. Vaginal delivery
H M F + (2) Amp. + Gent. Caesarean section
I M F + (2) Amp. + Gent. Vaginal delivery
J M F — — Vaginal delivery
K M F — — Vaginal delivery
L F F — — Vaginal delivery
M F F — — Vaginal delivery
N M B — — Vaginal delivery
O F B — — Vaginal delivery
P M B — — Vaginal delivery
Q M F — — Vaginal delivery
R F F — — Vaginal delivery
∗M, male; F, female.∗∗B, breast-feeding; F, formula feeding.†Amp. = ampicillin, Gent. = gentamicin. ‡ twins.
intravenous antibiotic treatment in the neonatal period on
the evolution of biﬁdobacterial colonization over time.
2.MaterialandMethods
2.1.Subjects. Faecalmaterialwassampled,usingswabs,from
18 infants, nine infants previously treated with antibiotics
and nine healthy controls (Table 1). Approval for the study
protocol was obtained from the Clinical Research Ethics
Committee of the Cork Teaching Hospitals, Cork, Ireland.
Inclusion criteria were deﬁned as full or near term infants
requiring parenteral antibiotic administration within the
ﬁrst 48 hours of life. Control subjects were eligible if they
were full or near term infants who were otherwise well and
did not require admission to the NICU. Infants placed on
oral antibiotics, those kept nil by mouth or requiring surgery,
infants with congenital anomalies, or those born before term
were excluded from the study. The indications for antibiotic
treatment were determined clinically, based on symptoms
and/or signs of suspected sepsis, and independent of the
study investigators. Written informed consent was obtained
from parents of all infants. Stool samples were taken by the
same clinician at four and eight weeks after birth and stored
at −20
◦C pending analysis.
2.2.PCR-DGGEAnalysis. BacterialDN Awasextractedfrom
swabs using a QIAamp DNA stool minikit (Qiagen, Hilden,
Germany) by following the manufacturer’s instructions
(lysis temperature, 95
◦C). To investigate the biﬁdobacterial
population in the samples, PCR was performed as a nested
approach. The ﬁrst PCR applied primers Im26-f (5 -GAT-
TCTGGCTCAGGATGAACG-3 )a n dI m 3 - r( 5  -CGGGTG-
CTICCCCACTTTCATG-3 ) described by Kaufmann et al.
[18] ampliﬁed a 1,417bp fragment of the biﬁdobacterial
16S rRNA gene. PCR volumes of 50µL contained 5µLo f
10× PCR buﬀer, 5µLo fM g C l 2 (2.5mM), 8µLo fd N T P s
(0,2mM each), 1µL of each primer (5pmol), 0.5µLo fT a q
polymerase (5U/µL), 28.5µLo fs t e r i l eM i l l i - Qw a t e r ,a n d
1µL of DNA solution. PCR-reagents were obtained from
Bioline (Taunton, MA, USA). The following PCR program
was used: initial denaturation at 94
◦C for 5min; 3 cycles
of denaturation at 94
◦C for 45s, annealing at 57
◦Cf o r
2minutes, and extension at 72◦C for 1min; 30 cycles of
denaturation at 94
◦C for 20s, annealing at 57
◦C for 1min,
and extension at 72
◦C for 1min; and ﬁnal extension at
72
◦C for 5min followed by cooling to 4◦C. The presence
of PCR products was veriﬁed on a 1.5% (w/v) agarose
gel. In order to eliminate the remaining oligonucleotides
and original template DNA, puriﬁcation of the amplicons
was performed by use of the QIAquick PCR puriﬁcation
kit (Qiagen) according to the manufacturer’s instructions.
A second PCR was performed using the amplicons of the
ﬁrst PCR as template DNA. The primer set used (F357-
GC and 518R) (5 GC-clamp-GCCTACGGAGGCAGCAG-
3  and 5 -ATTACCGCGGCTGCTGG-3 , resp.) ampliﬁes
the V3 region of the bacterial 16S rRNA gene [19]. The
forward primer contained a GC clamp (5 -CGCCCGCCG-
CGCGCGGCGGGCGGGGCGGGGGCACGGGGG-3 )t o
facilitate separation of the amplicons in a DGGE gel. PCR
volumes of 50µL contained 5µLo f1 0 × PCR buﬀer, 2µLo f
MgCl2 (1mM), 8µL of dNTPs (0.2mM each), 2µLo fe a c h
primer (5µM), 0.5µL of Taq polymerase (5 U/µL), 29.5µ
L of sterile Milli-Q water, and 1µL of 10-fold diluted DNA
solution (obtained from the ﬁrst PCR). The following PCR
program was used: initial denaturation at 94
◦C for 5min, 30
cycles of denaturation at 94
◦C for 20s, annealing at 58
◦Cf o rInternational Journal of Microbiology 3
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Figure 1: DGGE of biﬁdobacterial PCR-products (V3-region) from stool samples taken at four weeks of age from infants treated with
antibiotics D–I (a) and controls J–R (b). The mobility of the PCR products obtained in DGGE was compared to the PCR pattern of reference
strains obtained with the same primer set.
45s, and extension at 72
◦C for 1min, and ﬁnal extension
at 72
◦C for 7min, following by cooling to 4◦C. PCR
products were analyzed on DGGE gels based on the protocol
by Temmerman et al. [10]. A Dcode universal mutation
detection system (Bio-Rad Laboratories, Hercules, CA, USA)
was used, utilizing 16cm by 16cm by 1mm gels. Eight
percent polyacrylamide gels were prepared and run with 1×
TAE buﬀer diluted from 50× TAE buﬀer (2M Tris base,
1M glacial acetic acid, and 50mM EDTA). The denaturing
gradient was formed with two 8% acrylamide (acrylamide-
bis/acrylamide 40%) stock solutions (Severn Biotech Ltd,
Worcestershire, UK). A 100% denaturing solution contained
40% (v/v) formamide and 7.0M urea. The gels were poured
from the top by using a gradient maker (CBS Scientiﬁc
Linear Gradient Maker, Bio-Rad Laboratories) and a pump
(Bio-Rad Laboratories) and gradients of 50% to 70%
were used for the separation of the generated amplicons.
Before polymerization of the denaturing gel (24mL gradient
volume), a 6mL stacking gel without denaturing chemicals
was added, and the appropriate comb was subsequently
inserted.PCRampliconswereseparatedbyelectrophoresisat
a constant voltage of 60V in a 0.5 × TAE buﬀer at a constant
temperature of 60
◦C for 16h. Gels were stained in ethidium
bromide for 30min, allowing digital capturing of the DGGE
band proﬁles under UV light.
2.3. Reference Ladder. Am i x t u r eo fﬁ v ed i ﬀerent species of
biﬁdobacteria which are the most commonly isolated species
of biﬁdobacteria from the infant gastrointestinal tract (GIT)
[14, 20, 21] was used to create a reference ladder in order
to enable a visual comparison of the bands. DNA extraction
from the reference strains, Biﬁdobacterium breve, B. biﬁdum,
B. infantis, B. adolescentis, and B. longum, was performed
according to the method described by Hoﬀman and Winston
[22].
3. Results
Nine subjects were recruited to both control and antibiotic-
treated groups in this study. Their pertinent demographic
data are summarized in Table 1. While the gender distri-
bution and feeding history was similar in both groups,
the antibiotic treated infants were more likely to be born
by caesarean section (5/9 infants) and all control infants
were born by spontaneous vaginal delivery. Ampicillin and
gentamicin were the only antibiotics used and the median
duration of therapy was 2 days (range 2–9 days).
3.1. Development of the Biﬁdobacterium Population at Four
Weeks of Age. In order to investigate the population of
biﬁdobacteria in the samples, the Biﬁdobacterium-speciﬁc
primers Im-3 and Im-26 were used. Amplicons obtained
using these primers served as template DNA for the V3
primer combination V3R and V3F, during a second PCR
step. The mobility of the PCR products obtained by these
primers in DGGE was compared with the PCR pattern
of biﬁdobacteria reference strains. Because of the high
G+C content of biﬁdobacteria, the conventional 35% to
70% denaturing gradient was replaced with a 50% to 70%
denaturing gradient.
At four weeks of age, species of biﬁdobacteria were
detected in six out of nine infants treated with antibiotics
(subjectsA–I)andinallinfantsinthecontrolgroup(subjects
J–R). The samples from the antibiotic treated infants exhib-
ited a lower number of bands in the DGGE gel (Figure 1(a))
compared with controls (Figure 1(b))a tf o u rw e e k so fa g e ,
representing a less diverse population of biﬁdobacteria at
this age. Five of six infants in the antibiotic-treated group
showed a single dominant band, which corresponded to B.
longum (Figure 1(a)). All ﬁve infants had been treated with
intravenous ampicillin/gentamicin for two days and there
were both breast fed (subject F, G) and formula fed (subject
D, H, I) infants within this group. The sample lacking a band
in the position of B.longum wasobtained froman infant that
had received antibiotics for ﬁve days (subject E). According
to the band pattern of this subject, some Biﬁdobacterium
species were able to colonize this infant despite antibiotic
treatment for ﬁve days; that is, the lower band appears to be
B. biﬁdum, while the upper band is not comparable to any
of the species within the reference ladder. All samples from4 International Journal of Microbiology
BC DEF GH I
B. biﬁdum
B. breve
B. longum
B. infantis
B. adolescentis
(a)
JK L MN OPQR
B. biﬁdum
B. breve
B. longum
B. infantis
B. adolescentis
(b)
Figure 2: DGGE of biﬁdobacterial PCR-products (V3-region) from stool samples taken at eight weeks of age from infants treated with
antibiotics B–I (a) and controls J–R (b). The mobility of the PCR products obtained in DGGE was compared to the PCR pattern of reference
strains obtained with the same primer set.
the formula fed controls (K, L, M, Q, R) exhibited a band in
the same position as B. longum at four weeks of age, except
for one infant (subject J) (Figure 1(b)). In contrast, samples
from the breast fed infants in the control group (N, O, P)
showed bands in the positions of B. infantis and B. biﬁdum.
These two species were only found in one of the formula
fed infants. While all vaginally born infants in the antibiotic-
treated group harboured biﬁdobacteria by four weeks of age,
two out of ﬁve infants born by caesarean section harboured
biﬁdobacteria (B. biﬁdum and B. longum) at this time point.
3.2. Development of the Biﬁdobacterium Population at Eight
Weeks of Age. At eight weeks of age, eight out of nine
antibiotic-treated infants and all controls had detectable
levels of biﬁdobacteria in their stools. Interestingly, the only
sample in which biﬁdobacteria was not detected was from an
infant that had received antibiotics for nine days (subject A)
(the other infants were treated with antibiotics for 2–5 days).
Between four and eight weeks, an increase in biﬁdobacteria
diversity in both groups was observed as evidenced by the
increased number of bands (Figure 2). Nonetheless, while
both groups were similar at eight weeks, samples from
antibiotic-treated infants continued to display a less diverse
population of biﬁdobacteria when compared with controls
(Figure 2). The samples obtained from the breast-fed infants
inthecontrolgrouphadingeneralamorediversepopulation
of biﬁdobacteria compared with formula-fed infants (7-
8 bands compared with 2–5 bands, resp.). However, no
diﬀerences between the samples from the breast-fed and
formula-fed infants in the antibiotic-treated groups were
observed. Subject G exhibited a decrease in diversity from
four to eight weeks of age. Moreover, the band with highest
intensity at four weeks, identiﬁed as B. longum,w a sr e p l a c e d
by another dominant strain, identiﬁed as B. breve,a f t e r
eight weeks. Four of the ﬁve infants in the antibiotic-treated
group born by caesarean section harboured biﬁdobacteria by
week eight. As found at week four, all vaginally born infants
harboured biﬁdobacteria at eight weeks of age, with a higher
diversity observed compared with four weeks of age. Overall,
B. longum appeared to be the most commonly detected
Biﬁdobacterium species in the infants at eight weeks of life
(present in 15 out of 17 infants harbouring biﬁdobacteria)
(Figure 2).
4. Discussion
Biﬁdobacterium and Lactobacillus species are considered
among the most important beneﬁcial bacteria in the human
GIT and their presence in large numbers in the microbiota
is regarded as beneﬁcial [23, 24]. Suppression of these
beneﬁcial components could facilitate growth of potentially
pathogenic bacteria such as Klebsiella and Clostridium and
have consequences for the well-being of the host. This study
demonstrates that even brief parenteral antibiotic treatment
alters the pattern of biﬁdobacterial evolution over time.
Infants treated with antibiotics showed a reduction in both
colonisation and diversity of biﬁdobacteria compared with
controls. While control and antibiotic-treated groups were
similar by eight weeks of age, a number of control subjects
continued to display a more diverse population of biﬁdobac-
teria. Mackie et al. [25] reported that the colonisation of
biﬁdobacteria in infants is normally well established by one
week of age. It is tempting to speculate that the observed
diﬀerence in detectable levels of biﬁdobacteria between the
antibiotic-treated infants and controls in our study reﬂects
the early antibiotic exposure. Favier et al. [26] previously
describedasigniﬁcantdiﬀerenceinthemicrobiotaofasingle
infant receiving antibiotics compared to four nonantibiotic
treated infants, using similar methodology that is, PCR-
DGGE and Biﬁdobacterium-speciﬁc primers as used in our
study. Biﬁdobacterium spp. were absent in the antibiotic-
treated infant at all time points assessed, from ﬁve days to
ﬁve months of age. However, in that study, the antibiotic-
treated subject received prolonged antibiotic therapy with
both parenteral and oral agents (thirteen days of parenteral
coamoxiclav followed by oral cotrimoxazole) [26]. In con-
trast, the majority of participants in our study had relatively
brief periods of intravenous antibiotic administration and
yet diﬀerences were still observed compared with controls.
B. longum was the dominant species in both the
antibiotic-treated infants and in the control group. This
ﬁnding is consistent with the study by Gr¨ onlund et al.
[27] which found B. longum to be the most commonInternational Journal of Microbiology 5
Biﬁdobacteriumspeciespresentininfants.B.longumwasalso
the most prevalent species in the antibiotic-treated infants.
This result correlates with a recent ﬁnding by M¨ att¨ oe ta l .
[14], demonstrating that B. longum has a higher minimum
inhibitory concentration (MIC) for ampicillin compared
with other Biﬁdobacterium species. Thus, it appears that the
antibiotic treatment itself may have selected for this species.
One infant showed a decrease in numbers of species from
three species at four weeks of age to one species at eight
weeks of age. The species that showed the highest intensity
in the DGGE gel after four weeks was replaced by another
dominant species after eight weeks. These results are in
agreement with a study by Favier et al. [26] in which the
initiallydominantbiﬁdobacteriaintwoinfantswerereplaced
followingtheemergenceofnewspecieswithinthestudytime
period.
Although less than half of the infants in this study were
breast-fed, our study conﬁrms previous reports that breast-
feeding is positively associated with a more diverse biﬁ-
dobacterial population compared with formula-fed infants
[16, 28, 29]. Biﬁdobacterium species are considered among
the most important beneﬁcial bacteria in the human GIT
[18, 19, 24]. A higher density of beneﬁcial bacteria in
infants may confer a degree of protection against childhood
diseases. For example, biﬁdobacterial colonisation has been
associated with a lower risk of atopy [21, 30, 31]. In a
prospective study, children with lower numbers of fecal
biﬁdobacteria and increased numbers of clostridia from the
ﬁ r s tw e e k so fl i f ew e r em o r el i k e l yt ob e c o m es e n s i t i z e dt o
common allergens [23]. In addition, it has been reported
that diﬀerences in the gut microbiota during infancy may
precede the onset of obesity. In this study by Kalliom¨ aki et al.
[32],thenumbersofBiﬁdobacteriumspp.werehigherduring
infancy in children who remained at normal weight than
those in children who became overweight. Factors such as
breast-feeding, vaginal delivery, and the absence of antibiotic
exposure would promote microbial diversity with higher
numbers of biﬁdobacteria.
Inconclusion,thepresentstudydemonstratesthatshort-
term parenteral antibiotic treatment of neonates causes a
disturbance in the expected colonization pattern of biﬁ-
dobacteria in the ﬁrst months of life. Whether a delay in
biﬁdobacterial colonisation could adversely inﬂuence health
status, either in infancy or later life remains unknown.
However, adequately powered prospective studies that doc-
ument changes in the microbiota and incorporate long-
term health status outcomes are needed to further our
understanding of the sequelae, if any, of early neonatal
antibiotic administration. Until such data are available,
supplementation with biﬁdobacteria in this patient group
cannot be justiﬁed.
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